NO. CHELMSFORD, Mass.--(BUSINESS WIRE)--EndoEvolution, LLC, an emerging medical device company developing next-generation automated suturing devices for minimally invasive surgery (MIS) applications, announced today the licensing of the Endo360°™ MIS suturing device to Edwards Lifesciences Corporation. The license gives Edwards Lifesciences the exclusive worldwide rights to Endo360° for cardiac-related applications only.
EndoEvolution’s patented, FDA-cleared Endo360° device is the only automated MIS suturing device using curved needles and precisely replicating the traditional methods used by surgeons to place stitches and tie intracorporeal knots.
“We believe this partnership with Edwards demonstrates the important clinical potential of our next-generation, automated suturing device,” said Jerry Brecher, President and CEO of EndoEvolution.
Financial terms of the agreement were not disclosed.
EndoEvolution is a privately held medical device company introducing and developing the most advanced, next-generation MIS (Minimally Invasive Surgery) automated suturing devices with the potential to deliver significant clinical advantages, substantial cost-savings to hospitals, and catalyze substantial growth for the MIS sector. EndoEvolution’s reusable, next-generation automated suturing products are designed to be easier to use and easier to learn to use, more effective in surgery, and deliver substantial cost-savings to hospitals compared to other MIS automated suturing devices. EndoEvolution’s devices include Endo360°™ and the 5mm EndoTransformer™: the world’s only MIS suturing devices using curved needles and consequently the only automated suturing devices that precisely replicate the methods used by surgeons to place stitches and tie intracorporeal knots.